CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 123 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $49,321,016 | +37.7% | 3,307,915 | +1.1% | 0.02% | +47.1% |
| Q2 2023 | $35,828,487 | +27.4% | 3,272,008 | +1.5% | 0.02% | +21.4% |
| Q1 2023 | $28,120,797 | +19318.0% | 3,224,862 | +13862.3% | 0.01% | – |
| Q4 2022 | $144,818 | +78.8% | 23,097 | 0.0% | 0.00% | – |
| Q3 2022 | $81,000 | +12.5% | 23,097 | -5.6% | 0.00% | – |
| Q2 2022 | $72,000 | -8.9% | 24,464 | -3.9% | 0.00% | – |
| Q1 2022 | $79,000 | -24.0% | 25,452 | -17.5% | 0.00% | – |
| Q4 2021 | $104,000 | -75.1% | 30,833 | -73.0% | 0.00% | – |
| Q3 2021 | $417,000 | +334.4% | 114,218 | +419.1% | 0.00% | – |
| Q2 2021 | $96,000 | -4.0% | 22,003 | 0.0% | 0.00% | – |
| Q1 2021 | $100,000 | -21.3% | 22,003 | -0.9% | 0.00% | – |
| Q4 2020 | $127,000 | -22.1% | 22,210 | -1.2% | 0.00% | – |
| Q3 2020 | $163,000 | -90.4% | 22,487 | -98.0% | 0.00% | -100.0% |
| Q1 2020 | $1,704,000 | -24.5% | 1,151,356 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $2,257,000 | -61.7% | 1,151,356 | 0.0% | 0.00% | -66.7% |
| Q3 2019 | $5,895,000 | -28.5% | 1,151,356 | 0.0% | 0.00% | -25.0% |
| Q2 2019 | $8,244,000 | -44.7% | 1,151,356 | +2.5% | 0.00% | -50.0% |
| Q1 2019 | $14,917,000 | +9.3% | 1,123,256 | -35.2% | 0.01% | 0.0% |
| Q4 2018 | $13,647,000 | -29.0% | 1,734,100 | 0.0% | 0.01% | -20.0% |
| Q3 2018 | $19,214,000 | -20.4% | 1,734,100 | -3.6% | 0.01% | -16.7% |
| Q2 2018 | $24,139,000 | +3.3% | 1,798,700 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $23,365,000 | +75.3% | 1,798,700 | +24.2% | 0.01% | +100.0% |
| Q4 2017 | $13,328,000 | +10.2% | 1,448,700 | -3.4% | 0.01% | 0.0% |
| Q3 2017 | $12,090,000 | – | 1,500,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |